Journal
CELL TRANSPLANTATION
Volume 18, Issue 7, Pages 691-693Publisher
SAGE PUBLICATIONS INC
DOI: 10.3727/096368909X470883
Keywords
Stem cell transplantation; Tissue regeneration, Cellular therapy; Clinical translation
Funding
- NHLBI NIH HHS [R01 HL064766, R01HL 64766] Funding Source: Medline
- NINDS NIH HHS [P01 NS42345, P01 NS037520, P01 NS023393, P01 NS37520, R01NS38292, P01-NS042345, 1U01NS055914-01, R01 NS27292, R01 NS027292, R42 NS055606, U01 NS055914, P01 NS23393, R01 NS058784, R01 NS055728, P01 NS042345, R01 NS038292, 2R42NS055606-02] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064766] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS055914, R01NS055728, P01NS037520, R42NS055606, P01NS023393, R01NS038292, R01NS027292, R01NS058784, P01NS042345] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance front the laboratory to the clinic
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
